Myriad To Enter Neuroscience Market With $225m Assurex Acquisition
Executive Summary
In its bid to develop more targeted diagnostics and build future partnerships with pharma companies, Myriad has signed a $225m deal, plus milestones, to acquire Assurex Health.
You may also be interested in...
Device/Diagnostics Quarterly Deal Statistics, Q3 2016
Q3 medtech financing doubled in dollar volume to $3 billion, with debt offerings again representing the majority of the aggregate; acquisitions totaled $5.3 billion, mainly due to Johnson & Johnson’s $4.3 billion buy of Abbott Medical Optics. Diagnostics financings, which brought in $85 million, continued to decline, but at $5 billion, acquisitions showed a slight increase over the previous quarter, with Danaher’s takeover of Cepheid accounting for most of the M&A volume.
August M&A Analysis: Slow Month Highlighted By Unique Technologies
The dog-days of summer produced just a handful of mergers and acquisitions in the medtech sector and no blockbuster deals. However, several companies made smaller deals for innovative products in a range of sectors including IVDs, cardiovascular devices, and ophthalmology.
Myriad's myChoice To Be Used In More Cancer Clinical Trials
Myriad is continuing its mission to expand its companion diagnostics reach by teaming up with Tesaro and Merck to evaluate their breast and ovarian cancer drugs, and expanding its partnership with Abbvie into lung cancer. .